Kenvue (KVUE) Expected to Announce Quarterly Earnings on Thursday

Kenvue (NYSE:KVUE) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $3.94 billion for the quarter. Kenvue has set its FY 2025 guidance at EPS.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 earnings per share. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

Shares of KVUE opened at $21.71 on Thursday. The stock has a 50 day moving average price of $21.91 and a 200 day moving average price of $22.37. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $41.65 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 3.71 and a beta of 0.83. Kenvue has a 52-week low of $18.10 and a 52-week high of $25.17.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 3.82%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 149.09%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KVUE. Bank of America lowered their price target on Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, July 15th. JPMorgan Chase & Co. decreased their price objective on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. Citigroup decreased their price objective on Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a report on Tuesday, July 15th. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective for the company. Finally, UBS Group decreased their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $24.79.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.